Log in to search using one of your social media accounts:

 

PaRTNer: Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer A Pilot, Survey Based Study
Condition:   Head and Neck Cancer Intervention:   Other: Demographics questionnaires and the FACT HN questionnaire Sponsor:   Duke University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2018 Category: Research Source Type: clinical trials

The effect of regularly dosed paracetamol versus no paracetamol on renal function in Plasmodium knowlesi malaria (PACKNOW): study protocol for a randomised controlled trial
This study aims to assess the ability of regularly dosed paracetamol to reduce the incidence and severity of AKI in knowlesi malaria by attenuating haemolysis-induced oxidative damage.MethodsPACKNOW is a two-arm, open-label randomised controlled trial of adjunctive paracetamol versus no paracetamol in patients aged ≥ 5 years with knowlesi malaria, conducted over a 2-year period at four hospital sites in Sabah, Malaysia. The primary endpoint of change in creatinine from enrolment to 72 h will be evaluated by analysis of covariance (ANCOVA) using enrolment creatinine as a covariate. Secondary endpoints in...
Source: Trials - April 24, 2018 Category: Research Source Type: clinical trials

CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
DiscussionThe outcome of this trial will provide evidence of the potential benefit of the use of nivolumab in the treatment of relapsed mesothelioma. If found to be clinically effective, safe and cost-effective it is likely to become the new standard of care in the UK.Trial registrationEudraCT Number: 2016 –003111-35 (entered on 21 July 2016); ClinicalTrials.gov, ID:NCT03063450. Registered on 24 February 2017. (Source: Trials)
Source: Trials - April 18, 2018 Category: Research Source Type: clinical trials

Smoking Topography Study 2018
Conditions:   Cigarette Smoking;   Smoking Behavior;   Cigarette Smoking Toxicity Interventions:   Behavioral: Marlboro;   Behavioral: Marlboro Prime;   Behavioral: Marlboro Prime (ventilation holes taped) Sponsor:   Maastricht University Medical Center Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 13, 2018 Category: Research Source Type: clinical trials

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial
This article displays the key elements of the study protocol.Methods/designSURF [NCT02689167] is a prospective, randomized, open-label phase IIb study. Patients are included at sunitinib initiation while receiving standard schedule 4/2 (50  mg daily) according to the marketing authorization indication. When a dose adjustment of sunitinib is required, patients are randomized between standard schedule 4/2 (37.5 mg daily) and experimental schedule 2/1 (50 mg daily). Key eligibility criteria are the following: patients with locally adv anced inoperable or MRCC who are starting first-line treatment with sunitinib...
Source: Trials - April 12, 2018 Category: Research Source Type: clinical trials

The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products
Condition:   Nicotine Dependence, Cigarettes Interventions:   Drug: Nicotine patch;   Other: Placebo patch;   Other: E-cigarettes;   Other: Non-nicotine e-cigarettes Sponsors:   Duke University;   National Institute on Drug Abuse (NIDA) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2018 Category: Research Source Type: clinical trials

Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
Conditions:   Efficacy;   Toxicity Intervention:   Drug: Methylsulfonic apatinib Sponsors:   Peking University People's Hospital;   Peking University Shougang Hospital;   Peking University International Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2018 Category: Research Source Type: clinical trials

Prevention of Chest Pain in Chemo-treated Cancer-patients
Conditions:   Solid Carcinoma;   5-Fluorouracil Toxicity;   Cardiotoxicity;   Chemotherapeutic Toxicity;   Acute Coronary Syndrome;   Coronary Artery Calcification;   Chest Pain Interventions:   Diagnostic Test: Coronary artery calcium score 1;   Diagnostic Test: Coronary artery calcium score 2 Sponsors:   Vejle Hospital;   Region of Southern Denmark Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2018 Category: Research Source Type: clinical trials

Prevention of Chest Pain in Chemo-treated Cancer-patients
Conditions:   Solid Carcinoma;   5-Fluorouracil Toxicity;   Cardiotoxicity;   Chemotherapeutic Toxicity;   Acute Coronary Syndrome;   Coronary Artery Calcification;   Chest Pain Intervention:   Procedure: Cardiologic assessment Sponsors:   Vejle Hospital;   Region of Southern Denmark Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2018 Category: Research Source Type: clinical trials

Prevention of Chest Pain in Chemo-treated Cancer Patients
Conditions:   Solid Carcinoma;   5-Fluorouracil Toxicity;   Cardiotoxicity;   Chemotherapeutic Toxicity;   Acute Coronary Syndrome;   Coronary Artery Calcification;   Chest Pain Intervention:   Procedure: Cardiologic assessment Sponsors:   Vejle Hospital;   Region of Southern Denmark Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2018 Category: Research Source Type: clinical trials